Get the Stockscreener App
8.83
7.03%
0.58
Cervomed Inc stock is traded at $8.83, with a volume of 220.91K.
It is up +7.03% in the last 24 hours and up +48.90% over the past month.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$8.25
Open:
$8.07
24h Volume:
220.91K
Relative Volume:
0.57
Market Cap:
$76.85M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.5764
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
-1.67%
1M Performance:
+48.90%
6M Performance:
+290.71%
1Y Performance:
-28.56%
1-Day Range:
$7.8697
$9.00
1-Week Range:
$7.8697
$13.13
52-Week Range:
$1.80
$20.63
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
8.83 | 71.80M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
CervoMed Shares Surge After Promising Dementia Drug Trial Results - MSN
How volatile is CervoMed Inc. stock compared to the marketSwing Trade Updates For Consistent Profits - jammulinksnews.com
CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock - Stocktwits
CervoMed Inc. Forms Double Bottom Pattern — Eyes on BreakoutAlpha Driven Watchlist With Alerts Published - metal.it
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains? - MSN
Sentiment Turns Positive on CervoMed Inc. — Reversal AheadReliable Alerts for Daily Stock Movers Released - metal.it
Canaccord Genuity raises CervoMed stock price target to $27 on improved approval odds - Investing.com Nigeria
CervoMed (CRVO) Target Price Increased Following Positive Drug T - GuruFocus
Published on: 2025-07-29 09:25:15 - metal.it
Will CervoMed Inc. Benefit From Broader Market BounceAI Powered High Return Stock Calls Dominate Watchlists - metal.it
CervoMed Announces 32-Week Data from RewinD-LB Trial - GlobeNewswire
CervoMed Inc. Company’s Quarterly Earnings Growth: What the Numbers SayInvestment Strategy With Predictable Gains Outlined - metal.it
CervoMed Announces Positive Phase 2b Trial Results - TipRanks
What are CervoMed Inc. company’s key revenue driversExpert Picks Insights For Fast Growth - jammulinksnews.com
CRVO Stock Skyrockets: What’s Next? - StocksToTrade
CervoMed's Dementia Data Show Slowed Disease Progression - inkl
When is CervoMed Inc. stock expected to show significant growthHigh-impact stock picks - jammulinksnews.com
Why CervoMed Stock is Suddenly Booming - StocksToTrade
CRVO’s New Phase 2b Results: What’s Next? - timothysykes.com
How to monitor CervoMed Inc. with trend dashboardsFree News Based Entry Opportunity Alerts - Newser
CervoMed Stock Soars 63.36% on Positive Dementia Drug Trial Data - AInvest
Leading vs lagging indicators on CervoMed Inc. performanceMarket Downturn Defense Strategy Analysis - Newser
Best data tools to analyze CervoMed Inc. stockBuy Candidate Summary Based on Fundamentals - Newser
CervoMed stock soars after positive dementia drug trial data By Investing.com - Investing.com Nigeria
CervoMed stock soars after positive dementia drug trial data - Investing.com Australia
Combining machine learning predictions for CervoMed Inc.Price Spike Prediction for Active Traders - Newser
How does CervoMed Inc. generate profit in a changing economyFree Stock Selection - jammulinksnews.com
Will CervoMed Inc. benefit from macro trendsAI Generated Buy/Sell Signal Forecast - Newser
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Ne - GlobeNewswire
Breakthrough: New Dementia Treatment Cuts Disease Progression Risk by 64% in Major Clinical Trial Success - Stock Titan
How to track smart money flows in CervoMed Inc.Forecast Model for Intraday Buy Signals - Newser
How CervoMed Inc. stock performs during market volatilityAI Trading Forecast Based on Big Data - Newser
Combining machine learning predictions for CervoMed Inc. Reliable Setup Screener with Low Risk - Newser
Is CervoMed Inc. stock overvalued or undervaluedAchieve breakthrough gains with smart trades - jammulinksnews.com
CervoMed To Report 32-Week Extension Phase Results Of RewinD-LB Study Today - Nasdaq
What is CervoMed Inc. company’s growth strategySmart Portfolio Tracker For Smart Trading - jammulinksnews.com
Why is CervoMed Inc. stock attracting strong analyst attentionInvest in stocks with long-term growth potential - jammulinksnews.com
Is CervoMed Inc. a growth stock or a value stockGet timely alerts on top-performing stocks - jammulinksnews.com
Will CervoMed Inc. Stock Benefit from AI and Green Energy TrendsFree Stock Market Group - Newser
Should I hold or sell CervoMed Inc. stock in 2025Invest smarter with expert stock recommendations - jammulinksnews.com
Moving Average Trends for CervoMed Inc. Stock: What They IndicateDefensive Stock Picks with Upside - Newser
How Resilient Is CervoMed Inc. Stock During Economic DownturnsLow Risk Consistent Winners - Newser
D. Boral Capital Reiterates “Buy” Rating for CervoMed (NASDAQ:CRVO) - Defense World
What drives CervoMed Inc. stock priceExceptional trading performance - PrintWeekIndia
CervoMed (CRVO) Retains Buy Rating Amidst Steady Price Target | CRVO Stock News - GuruFocus
CervoMed to report 32-week extension phase results for DLB treatment By Investing.com - Investing.com South Africa
CervoMed to report 32-week extension phase results for DLB treatment - Investing.com
CervoMed Inc. to Present 32-Week Primary Endpoint Results from RewinD-LB Study at AAIC 2025 Conference Call on July 28 - Nasdaq
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):